{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:55:10Z","timestamp":1781920510274,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pharmacosmos A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Iron deficiency anemia is common in people with inflammatory bowel disease (IBD), causing deterioration in quality of life, which can be reversed by treatment that increases iron stores and hemoglobin levels. The present <jats:italic>post hoc<\/jats:italic> analyses estimate health state utility values for patients with IBD after treatment with ferric derisomaltose or ferric carboxymaltose and evaluate the health domains driving the changes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>SF-36v2 responses were recorded at baseline and day 14, 35, 49, and 70 from 97 patients enrolled in the randomized, double-blind, PHOSPHARE-IBD trial (ClinicalTrials.gov ID: NCT03466983), in which patients with IBD across five European countries were randomly allocated to either ferric derisomaltose or ferric carboxymaltose. Changes in SF-36v2 scale scores and SF-6Dv2 health utility values were analyzed by mixed models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In both treatment arms, SF-6Dv2 utility values and all SF-36v2 scale scores, except Bodily Pain, improved significantly (<jats:italic>p<\/jats:italic>\u2009=\u2009\u2009&lt;\u20090.0001). The improvement in SF-6Dv2 utility values showed no significant treatment group difference. The improvement in utility values was completely explained by improvement in Vitality scores. Vitality scores showed significantly larger improvement with ferric derisomaltose versus ferric carboxymaltose (<jats:italic>p<\/jats:italic>\u2009=\u20090.026). Patients with the smallest decrease in phosphate had significantly larger improvements in Vitality scores at each time point (<jats:italic>p<\/jats:italic>\u2009=\u2009\u2009&lt;\u20090.05 for all comparisons) and overall (<jats:italic>p<\/jats:italic>\u2009=\u20090.0006).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Utility values improved significantly with intravenous iron treatment. Improvement in utility values was primarily driven by Vitality scores, which showed significantly greater improvement in the ferric derisomaltose arm. Smaller decreases in phosphate were associated with significantly higher Vitality scores, suggesting that quality of life improvement is attenuated by hypophosphatemia. The utility values can inform future cost-utility analysis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11136-024-03642-y","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T10:01:55Z","timestamp":1718359315000},"page":"2285-2294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypophosphatemia attenuates improvements in vitality after intravenous iron treatment in patients with inflammatory bowel disease"],"prefix":"10.1007","volume":"33","author":[{"given":"J. B.","family":"Bjorner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. F.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"5","key":"3642_CR1","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/01.MIB.0000442728.74340.fd","volume":"20","author":"N Filmann","year":"2014","unstructured":"Filmann, N., Rey, J., Schneeweiss, S., Ardizzone, S., Bager, P., Bergamaschi, G., & Blumenstein, I. (2014). Prevalence of anemia in inflammatory bowel diseases in European countries: A systematic review and individual patient data meta-analysis. Inflammatory Bowel Diseases, 20(5), 936\u2013945. https:\/\/doi.org\/10.1097\/01.MIB.0000442728.74340.fd","journal-title":"Inflammatory Bowel Diseases"},{"issue":"7","key":"3642_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/17474124.2021.1900730","volume":"15","author":"Y Shah","year":"2021","unstructured":"Shah, Y., Patel, D., & Khan, N. (2021). Iron deficiency anemia in IBD: An overlooked comorbidity. Expert Review of Gastroenterology & Hepatology, 15(7), 771\u2013781. https:\/\/doi.org\/10.1080\/17474124.2021.1900730","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"10","key":"3642_CR3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.crohns.2014.03.005","volume":"8","author":"S L\u00f6nnfors","year":"2014","unstructured":"L\u00f6nnfors, S., Vermeire, S., Greco, M., Hommes, D., Bell, C., & Avedano, L. (2014). IBD and health-related quality of life\u2014discovering the true impact. Journal of Crohn\u2019s & Colitis, 8(10), 1281\u20131286. https:\/\/doi.org\/10.1016\/j.crohns.2014.03.005","journal-title":"Journal of Crohn\u2019s & Colitis"},{"issue":"10","key":"3642_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/01.mib.0000179467.01748.99","volume":"11","author":"T Bernklev","year":"2005","unstructured":"Bernklev, T., Jahnsen, J., Lygren, I., Henriksen, M., Vatn, M., & Moum, B. (2005). Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: Psychometric assessments and a comparison with general population norms. Inflammatory Bowel Diseases, 11(10), 909\u2013918. https:\/\/doi.org\/10.1097\/01.mib.0000179467.01748.99","journal-title":"Inflammatory Bowel Diseases"},{"issue":"12","key":"3642_CR5","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1002\/ibd.21285","volume":"16","author":"MJL Romberg-Camps","year":"2010","unstructured":"Romberg-Camps, M. J. L., Bol, Y., Dagnelie, P. C., Hesselink-van de Kruijs, M. A. M., Kester, A. D. M., Engels, L. G. J. B., & Stockbr\u00fcgger, R. W. (2010). Fatigue and health-related quality of life in inflammatory bowel disease: Results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflammatory Bowel Diseases, 16(12), 2137\u20132147. https:\/\/doi.org\/10.1002\/ibd.21285","journal-title":"Inflammatory Bowel Diseases"},{"issue":"6","key":"3642_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/apt.14922","volume":"48","author":"L Peyrin-Biroulet","year":"2018","unstructured":"Peyrin-Biroulet, L., Lopez, A., Cummings, J. R. F., Dignass, A., Detlie, T. E., & Danese, S. (2018). Review article: Treating-to-target for inflammatory bowel disease-associated anaemia. Alimentary Pharmacology & Therapeutics, 48(6), 610\u2013617. https:\/\/doi.org\/10.1111\/apt.14922","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"6","key":"3642_CR7","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/MIB.0000000000000768","volume":"22","author":"C Herrera-deGuise","year":"2016","unstructured":"Herrera-deGuise, C., Casellas, F., Robles, V., Navarro, E., & Borruel, N. (2016). Iron deficiency in the absence of anemia impairs the perception of health-related quality of life of patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 22(6), 1450\u20131455. https:\/\/doi.org\/10.1097\/MIB.0000000000000768","journal-title":"Inflammatory Bowel Diseases"},{"issue":"2","key":"3642_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/01.MIB.0000196646.64615.db","volume":"12","author":"CW Wells","year":"2006","unstructured":"Wells, C. W., Lewis, S., Barton, J. R., & Corbett, S. (2006). Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflammatory Bowel Diseases, 12(2), 123\u2013130. https:\/\/doi.org\/10.1097\/01.MIB.0000196646.64615.db","journal-title":"Inflammatory Bowel Diseases"},{"key":"3642_CR9","doi-asserted-by":"publisher","first-page":"582163","DOI":"10.1155\/2015\/582163","volume":"2015","author":"C \u00c7eki\u00e7","year":"2015","unstructured":"\u00c7eki\u00e7, C., \u0130pek, S., Aslan, F., Akp\u0131nar, Z., Arabul, M., Topal, F., & \u00dcnsal, B. (2015). The effect of intravenous iron treatment on quality of life in inflammatory bowel disease patients with nonanemic iron deficiency. Gastroenterology Research and Practice, 2015, 582163. https:\/\/doi.org\/10.1155\/2015\/582163","journal-title":"Gastroenterology Research and Practice"},{"issue":"3","key":"3642_CR10","doi-asserted-by":"publisher","first-page":"otaa051","DOI":"10.1093\/crocol\/otaa051","volume":"2","author":"CL Coe","year":"2020","unstructured":"Coe, C. L., Meyers, M. H., Beaulieu, D. B., Scoville, E., Schwartz, D. A., Horst, S. N., & Dalal, R. L. (2020). Gastroenterologist-lead management of iron deficiency anemia in inflammatory bowel disease is effective, safe, and may increase quality of life. Crohn\u2019s & Colitis 360, 2(3), otaa051. https:\/\/doi.org\/10.1093\/crocol\/otaa051","journal-title":"Crohn\u2019s & Colitis 360"},{"issue":"10","key":"3642_CR11","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/ibd.20925","volume":"15","author":"JP Gisbert","year":"2009","unstructured":"Gisbert, J. P., Bermejo, F., Pajares, R., P\u00e9rez-Calle, J.-L., Rodr\u00edguez, M., Algaba, A., & Mat\u00e9, J. (2009). Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. Inflammatory Bowel Diseases, 15(10), 1485\u20131491. https:\/\/doi.org\/10.1002\/ibd.20925","journal-title":"Inflammatory Bowel Diseases"},{"issue":"3","key":"3642_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","volume":"9","author":"AU Dignass","year":"2015","unstructured":"Dignass, A. U., Gasche, C., Bettenworth, D., Birgeg\u00e5rd, G., Danese, S., Gisbert, J. P., European Crohn\u2019s and Colitis Organisation [ECCO]. (2015). European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. Journal of Crohn\u2019s & Colitis, 9(3), 211\u2013222. https:\/\/doi.org\/10.1093\/ecco-jcc\/jju009","journal-title":"Journal of Crohn\u2019s & Colitis"},{"issue":"2","key":"3642_CR13","doi-asserted-by":"publisher","first-page":"e2308","DOI":"10.1097\/MD.0000000000002308","volume":"95","author":"S Bonovas","year":"2016","unstructured":"Bonovas, S., Fiorino, G., Allocca, M., Lytras, T., Tsantes, A., Peyrin-Biroulet, L., & Danese, S. (2016). Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials. Medicine, 95(2), e2308. https:\/\/doi.org\/10.1097\/MD.0000000000002308","journal-title":"Medicine"},{"issue":"4","key":"3642_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","volume":"72","author":"H Zoller","year":"2023","unstructured":"Zoller, H., Wolf, M., Blumenstein, I., Primas, C., Lindgren, S., Thomsen, L. L., & Iqbal, T. (2023). Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): A randomised clinical trial. Gut, 72(4), 644\u2013653. https:\/\/doi.org\/10.1136\/gutjnl-2022-327897","journal-title":"Gut"},{"issue":"3","key":"3642_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11096-023-01548-2","volume":"45","author":"NA Kennedy","year":"2023","unstructured":"Kennedy, N. A., Achebe, M. M., Biggar, P., P\u00f6hlmann, J., & Pollock, R. F. (2023). A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. International Journal of Clinical Pharmacy, 45(3), 604\u2013612. https:\/\/doi.org\/10.1007\/s11096-023-01548-2","journal-title":"International Journal of Clinical Pharmacy"},{"key":"3642_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/CEOR.S284959","volume":"13","author":"RF Pollock","year":"2021","unstructured":"Pollock, R. F., & Muduma, G. (2021). An economic analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Norway, Sweden, and Finland. ClinicoEconomics and Outcomes Research, 13, 9\u201318. https:\/\/doi.org\/10.2147\/CEOR.S284959","journal-title":"ClinicoEconomics and Outcomes Research"},{"issue":"12","key":"3642_CR17","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1080\/17425247.2017.1393412","volume":"14","author":"RF Pollock","year":"2017","unstructured":"Pollock, R. F., & Muduma, G. (2017). Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: A budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opinion on Drug Delivery, 14(12), 1439\u20131446. https:\/\/doi.org\/10.1080\/17425247.2017.1393412","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"7","key":"3642_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","volume":"20","author":"I Blumenstein","year":"2021","unstructured":"Blumenstein, I., Shanbhag, S., Langguth, P., Kalra, P. A., Zoller, H., & Lim, W. (2021). Newer formulations of intravenous iron: A review of their chemistry and key safety aspects\u2014hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opinion on Drug Safety, 20(7), 757\u2013769. https:\/\/doi.org\/10.1080\/14740338.2021.1912010","journal-title":"Expert Opinion on Drug Safety"},{"issue":"4","key":"3642_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1210\/clinem\/dgab852","volume":"107","author":"B Schaefer","year":"2021","unstructured":"Schaefer, B., Zoller, H., & Wolf, M. (2021). Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose. Journal of Clinical Endocrinology and Metabolism, 107(4), 1009\u20131019. https:\/\/doi.org\/10.1210\/clinem\/dgab852","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"3642_CR20","doi-asserted-by":"publisher","first-page":"116202","DOI":"10.1016\/j.bone.2021.116202","volume":"154","author":"B Schaefer","year":"2022","unstructured":"Schaefer, B., Tobiasch, M., Wagner, S., Glodny, B., Tilg, H., Wolf, M., & Zoller, H. (2022). Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. Bone, 154, 116202. https:\/\/doi.org\/10.1016\/j.bone.2021.116202","journal-title":"Bone"},{"issue":"1","key":"3642_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"S Alatab","year":"2020","unstructured":"Alatab, S., Sepanlou, S. G., Ikuta, K., Vahedi, H., Bisignano, C., Safiri, S., & Naghavi, M. (2020). The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterology & Hepatology, 5(1), 17\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(19)30333-4","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"3642_CR22","volume-title":"User\u2019s manual for the SF-36v2 Health Survey","author":"M Maruish","year":"2011","unstructured":"Maruish, M. (2011). User\u2019s manual for the SF-36v2 Health Survey (3rd ed.). QualityMetric.","edition":"3"},{"issue":"6","key":"3642_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/MLR.0000000000001325","volume":"58","author":"JE Brazier","year":"2020","unstructured":"Brazier, J. E., Mulhern, B. J., Bjorner, J. B., Gandek, B., Rowen, D., Alonso, J., SF-6Dv2 International Project Group. (2020). Developing a new version of the SF-6D health state classification system from the SF-36v2: SF-6dv2. Medical Care, 58(6), 557\u2013565. https:\/\/doi.org\/10.1097\/MLR.0000000000001325","journal-title":"Medical Care"},{"issue":"6","key":"3642_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/MLR.0000000000001324","volume":"58","author":"BJ Mulhern","year":"2020","unstructured":"Mulhern, B. J., Bansback, N., Norman, R., Brazier, J., SF-6Dv2 International Project Group. (2020). Valuing the SF-6Dv2 classification system in the United Kingdom using a discrete-choice experiment with duration. Medical Care, 58(6), 566\u2013573. https:\/\/doi.org\/10.1097\/MLR.0000000000001324","journal-title":"Medical Care"},{"key":"3642_CR25","doi-asserted-by":"publisher","first-page":"468675","DOI":"10.1155\/2015\/468675","volume":"2015","author":"S Hardy","year":"2015","unstructured":"Hardy, S., & Vandemergel, X. (2015). Intravenous iron administration and hypophosphatemia in clinical practice. International Journal of Rheumatology, 2015, 468675. https:\/\/doi.org\/10.1155\/2015\/468675","journal-title":"International Journal of Rheumatology"},{"issue":"11","key":"3642_CR26","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s00467-012-2175-z","volume":"27","author":"M Goretti Penido","year":"2012","unstructured":"Goretti Penido, M., & Alon, U. S. (2012). Phosphate homeostasis and its role in bone health. Pediatric Nephrology, 27(11), 2039\u20132048. https:\/\/doi.org\/10.1007\/s00467-012-2175-z","journal-title":"Pediatric Nephrology"},{"issue":"10","key":"3642_CR27","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.eprac.2022.07.005","volume":"28","author":"PJ Tebben","year":"2022","unstructured":"Tebben, P. J. (2022). Hypophosphatemia: A practical guide to evaluation and management. Endocrine Practice, 28(10), 1091\u20131099. https:\/\/doi.org\/10.1016\/j.eprac.2022.07.005","journal-title":"Endocrine Practice"},{"issue":"10","key":"3642_CR28","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/imj.13937","volume":"48","author":"BD Jackson","year":"2018","unstructured":"Jackson, B. D., Con, D., Gorelik, A., Liew, D., Knowles, S., & De Cruz, P. (2018). Examination of the relationship between disease activity and patient-reported outcome measures in an inflammatory bowel disease cohort. Internal Medicine Journal, 48(10), 1234\u20131241. https:\/\/doi.org\/10.1111\/imj.13937","journal-title":"Internal Medicine Journal"},{"issue":"1","key":"3642_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12325-019-01151-w","volume":"37","author":"A Nocerino","year":"2020","unstructured":"Nocerino, A., Nguyen, A., Agrawal, M., Mone, A., Lakhani, K., & Swaminath, A. (2020). Fatigue in inflammatory bowel diseases: Etiologies and management. Advances in Therapy, 37(1), 97\u2013112. https:\/\/doi.org\/10.1007\/s12325-019-01151-w","journal-title":"Advances in Therapy"},{"issue":"10","key":"3642_CR30","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1155\/2014\/792386","volume":"28","author":"W El-Matary","year":"2014","unstructured":"El-Matary, W. (2014). Patient-reported outcome measures in inflammatory bowel disease. Canadian Journal of Gastroenterology & Hepatology, 28(10), 536\u2013542. https:\/\/doi.org\/10.1155\/2014\/792386","journal-title":"Canadian Journal of Gastroenterology & Hepatology"},{"issue":"5","key":"3642_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cgh.2017.12.027","volume":"16","author":"ER Cohen","year":"2018","unstructured":"Cohen, E. R., & Melmed, G. Y. (2018). Making a case for patient-reported outcomes in clinical inflammatory bowel disease practice. Clinical Gastroenterology and Hepatology, 16(5), 603\u2013607. https:\/\/doi.org\/10.1016\/j.cgh.2017.12.027","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"1","key":"3642_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izz104","volume":"26","author":"KT Park","year":"2020","unstructured":"Park, K. T., Ehrlich, O. G., Allen, J. I., Meadows, P., Szigethy, E. M., Henrichsen, K., & Heller, C. A. (2020). The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & Colitis Foundation. Inflammatory Bowel Diseases, 26(1), 1\u201310. https:\/\/doi.org\/10.1093\/ibd\/izz104","journal-title":"Inflammatory Bowel Diseases"},{"issue":"8","key":"3642_CR33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin, M., Slaap, B., Herdman, M., van Reenen, M., Kennedy-Martin, T., Greiner, W., & Boye, K. S. (2020). Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. European Journal of Health Economics, 21(8), 1245\u20131257. https:\/\/doi.org\/10.1007\/s10198-020-01195-8","journal-title":"European Journal of Health Economics"},{"issue":"293","key":"3642_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2307\/2282330","volume":"56","author":"OJ Dunn","year":"1961","unstructured":"Dunn, O. J. (1961). Multiple comparisons among means. Journal of the American Statistical Association, 56(293), 52\u201364. https:\/\/doi.org\/10.2307\/2282330","journal-title":"Journal of the American Statistical Association"},{"issue":"4","key":"3642_CR35","doi-asserted-by":"publisher","first-page":"800","DOI":"10.2307\/2336325","volume":"75","author":"Y Hochberg","year":"1988","unstructured":"Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika, 75(4), 800\u2013802. https:\/\/doi.org\/10.2307\/2336325","journal-title":"Biometrika"},{"issue":"318","key":"3642_CR36","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2307\/2283989","volume":"62","author":"Z Sidak","year":"1967","unstructured":"Sidak, Z. (1967). Rectangular confidence regions for the means of multivariate normal distributions. Journal of the American Statistical Association, 62(318), 626\u2013633. https:\/\/doi.org\/10.2307\/2283989","journal-title":"Journal of the American Statistical Association"},{"issue":"3","key":"3642_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2307\/2531989","volume":"43","author":"SJ Pocock","year":"1987","unstructured":"Pocock, S. J., Geller, N. L., & Tsiatis, A. A. (1987). The analysis of multiple endpoints in clinical trials. Biometrics, 43(3), 487\u2013498.","journal-title":"Biometrics"},{"issue":"7","key":"3642_CR38","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/sim.4780100712","volume":"10","author":"S James","year":"1991","unstructured":"James, S. (1991). Approximate multinormal probabilities applied to correlated multiple endpoints in clinical trials. Statistics in Medicine, 10(7), 1123\u20131135. https:\/\/doi.org\/10.1002\/sim.4780100712","journal-title":"Statistics in Medicine"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03642-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-024-03642-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03642-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T09:28:37Z","timestamp":1722245317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-024-03642-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3642"],"URL":"https:\/\/doi.org\/10.1007\/s11136-024-03642-y","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"assertion":[{"value":"27 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RFP is a shareholder, director and full-time employee of Covalence Research Ltd, which received consultancy fees from Pharmacosmos A\/S to prepare the data for analysis and prepared the draft manuscript. JBB is Chief Science Officer for QualityMetric, which received consultancy fees from Pharmacosmos A\/S to perform the data analyses. NK has received speaker honoraria, support for meetings and\/or travel, and participation in an advisory board from Pharmacosmos A\/S. SL has no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was based on patient-level data from the PHOSPHARE-IBD trial, which involved human participants and was conducted in line with the Declaration of Helsinki. All patients gave informed consent to participate in the study, and the study was approved by Institutional Review Boards at all participating centers as detailed by Zoller et al. (2022) [].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}